

# Review of the adaptations in opioid agonist treatment during the COVID-19 pandemic: Focus on buprenorphine-based treatment



**Abhishek Ghosh**

Associate Professor of Psychiatry & Addiction Psychiatry  
Department of Psychiatry  
Postgraduate Institute of Medical Education & Research, Chandigarh

---

---

---

---

---

---

---

---

## Acknowledgment and Conflict of Interest

- Ghosh A, Naskar C, Roub FE, Basu D. Review of the adaptations in opioid agonist treatment during the COVID-19 pandemic: Focus on buprenorphine-based treatment. *J Opioid Manag.* 2021;17(7):119-131. doi: 10.1016/j.jom.2021.06.49.



- I do not have any competing interest

---

---

---

---

---

---

---

---

## Background and Methods

- Discussed by Prof. D. Basu

---

---

---

---

---

---

---

---

## Results

- Number of articles: 21
- Method: Narrative review and synthesis

---

---

---

---


---

---

---

---

## Results: *Subsections*




---

---

---

---

---

---

---

---

## Buprenorphine *Initiation*




---

---

---

---

---


---

---

---

Qureshi A, Nadeer C, Rishi FE, Bhat D. Review of the adaptations in opioid agonist treatment during the COVID-19 pandemic: Focus on buprenorphine-based treatment. J Opioid Manag. 2021;17(1):119-131.

### Buprenorphine *Initiation* in India




---

---

---

---


---

---

---

---

### Buprenorphine *Dosing & Dispensing*



Gleason A, Nasser C, Roubi F-E, Beau D. Review of the adaptations in opioid agonist treatment during the COVID-19 pandemic: Focus on buprenorphine-based treatment. J Opioid Manag. 2021;15(1):119-121.

---

---

---

---


---

---

---

---

### Buprenorphine *Dosing & Dispensing* in India



Beau D, Gleason A, Sabath BN, et al. Opioid substitution therapy with buprenorphine-naloxone during COVID-19 outbreak in India: Sharing our experience and interim standard operating procedure. Indian J Psychiatry 2020; 62(6): 561-565.  
Gleason A, Singh S, Datta A. Opioid agonist treatment during SARS-CoV2 & extended lockdown: Adaptations & challenges in the Indian context. Asian J Psychiatry 2020; 15: 102777.

---

---

---

---


---

---

---

---

### Buprenorphine *and* Telemedicine



Qinsh A, Nankar C, Road F.E, Beau D. Review of the adaptations in opioid agonist treatment during the COVID-19 pandemic: Focus on buprenorphine-based treatment. J Opioid Manag. 2021;17(7):119-131.

---

---

---

---

---

---


---

---

---

---

### Special Population: *Prisons*



Qinsh A. Prisoners with drug use disorders during covid-19 pandemic: Caught between a rock and a hard place. Asian J Psychiatr. 2020;Dec;54:1102302.

---

---

---

---

---

---

---

---

---

---

### Special Population: *Homeless*



Qinsh A, Nankar C, Road F.E, Beau D. Review of the adaptations in opioid agonist treatment during the COVID-19 pandemic: Focus on buprenorphine-based treatment. J Opioid Manag. 2021;17(7):119-131.

---

---

---

---

---

---

---

---

---

---

### Impact of OAT Adaptations

USA	Ukraine	Australia
<ul style="list-style-type: none"><li>• Texas: high initiation, no increase in prescribers, reduced number on maintenance</li></ul>	<ul style="list-style-type: none"><li>• Increased proportion on BPN</li><li>• No increased mortality</li><li>• Reduced clinic interaction</li></ul>	<ul style="list-style-type: none"><li>• New South Wales: coordinated attempt between prisons and healthcare services</li></ul>

**BPN is safe in patients with moderate COVID-19**

---

---

---

---


---

---

---

---

### Implication and Limitation



---

---

---

---

---

---

---

---



[ghosh.abhishek@pgimer.edu.in](mailto:ghosh.abhishek@pgimer.edu.in)



---

---

---

---

---

---

---

---